Botulinum Toxin for the Treatment of Sialorrhea: A Meta-analysis

Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Otolaryngology Head and Neck Surgery (Impact Factor: 2.02). 10/2012; 148(2). DOI: 10.1177/0194599812465059
Source: PubMed


Botulinum toxin has emerged as an effective approach for the management of sialorrhea. This study presents a critical literature review and meta-analysis to determine the impact of botulinum toxin on drooling severity in patients with sialorrhea.Data SourcesOvid MEDLINE and the Cochrane databases.Review Methods
The above sources were searched to identify studies examining botulinum toxin for the treatment of sialorrhea. Included studies were randomized, placebo-controlled trials. Excluded studies failed to report quantifiable outcome measures of drooling severity at 4 weeks postintervention.ResultsEight studies involving 181 patients (83 placebo; 98 active) were included in the analysis. Botulinum toxin was found to significantly decrease the severity of drooling in patients with sialorrhea (standardized mean difference [SMD], -1.54; 95% confidence interval [CI], -2.05 to -1.04; P = .06; I(2) = 48%) when compared with placebo control using random effects models. The effect was significant in both adult (SMD, -1.29; 95% CI, -1.88 to -0.71) and pediatric (SMD, -1.84; 95% CI, -2.67 to -1.00) populations. Both botulinum toxin A (SMD, -1.53; 95% CI, -2.27 to -0.79) and B (SMD, -1.56; 95% CI, -2.32 to -0.79) produced similar effects. Botulinum toxin doses greater than 50 U (SMD, -3.81; 95% CI, -6.19 to -1.43) produced much stronger effects compared with doses less than or equal to 50 U (SMD, -1.32; 95% CI, -2.28 to -0.36).Conclusion
Botulinum toxin is a clinically effective therapy that improves drooling severity in patients with sialorrhea. Future studies will need to further evaluate the technique and examine dosages required to achieve optimal outcomes.

24 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In otorhinolaryngology, botulinum toxin is a suitable therapeutic option in the muscular and the autonomic nervous system concerning dysfunctions. Respecting some special aspects, it is an effective treatment for disorders of different etiology with very few side-effects. The positive therapeutic effect is temporarily limited, so that the patients need further treatment. Beside the classical indications like the facial hyperkinesias (i.e. blepharospasms, hemifacial spasm) the treatment of complex dystonias (oromandibular dystonia, laryngeal dystonia, cervical dystonia), gustatory sweating, hypersalivation and crocodile tears is successful. Botulinum toxin is an alternative treatment of tension type headache and migraine. A new indication of botulinum toxin application may lay in the treatment of nasal hypersecretion through the effect on the nasal glands.
    Laryngo-Rhino-Otologie 04/2003; 82(3):202-13; quiz 214-8. DOI:10.1055/s-2003-38407 · 0.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical features, anatomy and physiology of hyperhidrosis are presented with a review of the world literature on treatment. Level of drug efficacy is defined according to the guidelines of the American Academy of Neurology. Topical agents (glycopyrrolate and methylsulfate) are evidence level B (probably effective). Oral agents (oxybutynin and methantheline bromide) are also level B. In a total of 831 patients, 1 class I and 2 class II blinded studies showed level B efficacy of OnabotulinumtoxinA (A/Ona), while 1 class I and 1 class II study also demonstrated level B efficacy of AbobotulinumtoxinA (A/Abo) in axillary hyperhidrosis (AH), collectively depicting Level A evidence (established) for botulinumtoxinA (BoNT-A). In a comparator study, A/Ona and A/Inco toxins demonstrated comparable efficacy in AH. For IncobotulinumtoxinA (A/Inco) no placebo controlled studies exist; thus, efficacy is Level C (possibly effective) based solely on the aforementioned class II comparator study. For RimabotulinumtoxinB (B/Rima), one class III study has suggested Level U efficacy (insufficient data). In palmar hyperhidrosis (PH), there are 3 class II studies for A/Ona and 2 for A/Abo (individually and collectively level B for BoNT-A) and no blinded study for A/Inco (level U). For B/Rima the level of evidence is C (possibly effective) based on 1 class II study. Botulinum toxins (BoNT) provide a long lasting effect of 3-9 months after one injection session. Studies on BoNT-A iontophoresis are emerging (2 class II studies; level B); however, data on duration and frequency of application is inconsistent.
    Toxins 05/2013; 5(4):821-40. DOI:10.3390/toxins5040821 · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis is a neurodegenerative disease with a survival rate up to 5 years of 20%. It is characterized by the damage of the first and second motor neurons in a progressive course. There is no cure for this disease at the moment. Nevertheless, new treatments are being developed with the haunting shadow of not few drugs that were proven to be ineffective in stopping or slowing the disease progression. As a result, the main treatment objective at the moment is to soothe the complications the disease inexorably generates in its course. In this review we describe the signs and symptoms of the disease progression and its therapeutic options, for which we have reviewed national and international publications, as well as shearing the experience in our centre. The main topics developed are: weakness, sialorrhea, bronchial secretions, pseudobulbar affect, cramps, spasticity, respiratory insufficiency, limb edema, depression and dysphagia. We would like to point out that in spite of the general belief that «there is nothing left to do» we are summarizing a few, and only a few, of the therapeutic tools available for aiding the patients affected with ALS.
    Neurologia Argentina 04/2014; 6(2). DOI:10.1016/j.neuarg.2014.02.004
Show more